A PHASE I STUDY OF ERY974 IN PATIENTS WITH GPC3-POSITIVE ADVANCED SOLID TUMORS

A PHASE I STUDY OF ERY974 AS A SINGLE AGENT IN PATIENTS WITH GPC3-POSITIVE ADVANCED SOLID TUMORS

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080224729

Enrollment

Registered

2019-06-18

Start date

2019-11-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

advanced/recurrent solid tumors

Interventions

investigational material(s) Generic name etc : ERY974 INN of investigational material : - Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational material

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Aged >18 years at time of informed consent Eastern Cooperative Oncology Group(ECOG) Peformance Status(PS) of 0 or 1 Life expectancy >12 weeks from date of enrollment Histologically or cytologically documented solid tumor Advanced or recurrent cancer for which standard therapy is ineffective or inappropriate, or for which no standard therapy exists Documented GPC3 positivity

Exclusion criteria

Exclusion criteria: - Concurrent or prior autoimmune disease - Uncontrolled diabetes mellitus - Advanced/recurrent hepatocellular carcinoma - Concurrent New York Heart Association (NYHA) Class >II congestive heart failure, myocardial infarction, arrhythmia, or unstable angina, or a history thereof within 6 months before enrollment - Concurrent symptomatic cerebrovascular disorder or a history thereof within 6 months before enrollment

Design outcomes

Primary

Measure	Time frame
safety pharmacokinetics NCI CTCAE	—

Secondary

Measure	Time frame
efficacy RECIST	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026